Pannexin 1 Channel Blockers:
Controlling Key Neuroinflammatory and
Immune Drivers in Neurology and Oncology.

Pannex Therapeutics is building a platform to harness the broad therapeutic potential of Panx1 blockade across neurology and oncology, addressing large and critical unmet medical needs.

Learn more

Discover our science

Pannexin 1

Panx1 is a master regulator of pathological ATP release that drives immune amplification, chronic inflammation, and immune dysregulation across neurological diseases and cancer.

Science

Our team

David Bravo PhD

Chief Executive Officer &
Co-founder

Pannexin 1 research leader with more than a decade of success in drug discovery and innovation

Thomas Gerlach PhD

Chief Strategic Officer &
Co-founder

Biochemist with over 30 years of experience in global drug development, commercialization and venture capital

Gerhard Gross PhD

Chief Scientific Officer &
Co-founder

Chemist with 30 years of experience in drug discovery and development - 14 FDA - approved drugs
Team